sever
acut
respiratori
syndrom
sar
rapidonset
atyp
pneumonia
first
identifi
epidem
proport
china
recent
announc
contain
latest
outbreak
centr
nation
institut
virolog
beij
today
lancet
alexand
bukreyev
colleagu
show
singl
intranas
immunis
african
green
monkey
attenu
bovinehuman
parainfluenza
viru
type
envelop
spike
protein
sar
coronaviru
sarscov
express
induc
neutralis
antibodi
sarscov
serum
protect
subsequ
livevir
challeng
sarscov
find
import
sinc
bring
togeth
known
yet
innov
technolog
knowledg
skill
address
prevent
emerg
infecti
diseas
applic
gener
result
could
repres
major
step
forward
simplifi
mass
immunis
atrisk
human
popul
basi
protein
coronavirus
induc
virusspecif
immun
case
protect
subsequ
challeng
anim
model
bukreyev
colleagu
use
welldocu
carrier
vector
bhpiv
creat
liveattenu
vaccin
protect
monkey
challeng
sarscov
sever
anim
virus
display
type
stabl
hostrang
restrict
led
develop
jennerian
approach
liveattenu
vaccin
use
creat
vector
chimer
vector
import
potenti
induc
protect
immun
respons
respiratori
syncyti
viru
b
human
parainfluenza
viru
type
rhesu
monkey
hamster
human
trial
show
liveattenu
bovin
parainfluenza
viru
type
safe
immunogen
stabl
infant
children
produc
enhanc
immunogen
diseas
rhesu
monkey
data
yet
avail
use
chimer
vector
human
trial
intranas
liveattenu
viral
vector
offer
best
possibl
induc
sustain
protect
immun
via
mucos
rout
hostrestrict
approach
attenu
seen
power
adjuv
requir
system
mucos
immun
respons
gener
exacerb
diseas
natur
exposur
seem
occur
addit
mucos
immunis
offer
advantag
mucos
immun
mechan
seem
matur
earlier
young
children
wane
later
elderli
peopl
system
immun
mechan
despit
promis
demonstr
jennerian
approach
particular
intranas
vaccin
need
know
lag
mucos
system
immun
mechan
effect
also
durat
immun
induc
bukreyev
colleagu
report
challeng
monkey
sarscov
day
immunis
whilst
immunis
gave
excel
protect
viral
shed
day
serum
concentr
antibodi
immunis
anim
greater
day
postchalleng
measur
nonimmunis
anim
studi
examin
mucos
immun
respons
induc
sarscov
role
immun
protect
need
done
doserespons
studi
immunis
challeng
also
need
model
adopt
human
trial
indic
bukreyev
colleagu
approach
use
replic
chimer
viral
vector
protein
insert
common
human
respiratori
pathogen
might
limit
infant
small
children
interfer
neutralis
antibodi
develop
natur
infect
investig
warrant
establish
vector
construct
would
effect
age
group
especi
increas
mortal
rate
sar
elderli
peopl
possibl
immuoprophylaxi
treatment
highrisk
individu
becom
expos
sarscov
outlin
research
letter
also
today
lancet
jan
ter
meulen
colleagu
research
describ
preliminari
experi
ferret
speci
natur
infect
sarscov
found
prophylact
treatment
infect
anim
human
monoclon
antibodi
direct
cellsurfac
spike
glycoprotein
sarscov
abrog
viral
shed
pharynx
prevent
develop
macroscop
lung
diseas
infect
anim
extrapol
human
be
prophylact
treatment
reduc
viral
shed
lung
lesion
would
probabl
reduc
transmiss
high
morbid
associ
diseas
strategi
combin
immunis
sar
outbreak
would
offer
potenti
treatment
prophylact
applic
howev
monoclon
antibodi
approach
suggest
ter
meulen
appli
human
be
sever
studi
requir
particular
import
experi
relat
efficaci
immunoprophylaxi
treatment
presenc
establish
infect
appropri
doserespons
safeti
studi
critic
studi
effect
circul
antibodi
vaccin
efficaci
bukreyev
ter
meulen
colleagu
shown
sar
effect
prevent
immunis
mucosa
respiratori
tract
immunoprophylaxi
anim
model
whilst
studi
requir
concept
appli
human
be
find
provid
excit
strategi
prevent
diseas
target
commun
treatment
atrisk
individu
